Targeting of <i>HER2</i>-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

Abstract

The biodistribution of (111)In-ABY-025 was in remarkably good agreement with the parent tracers, despite profound reengineering of the nonbinding surface. The molecule displayed rapid blood clearance in all species investigated and excellent targeting capacity in tumor-bearing mice, leading to high tumor-to-organ-ratios and high-contrast imaging shortly after injection.